134 related articles for article (PubMed ID: 37498055)
21. Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphoma.
Pasqualucci L; Migliazza A; Basso K; Houldsworth J; Chaganti RS; Dalla-Favera R
Blood; 2003 Apr; 101(8):2914-23. PubMed ID: 12515714
[TBL] [Abstract][Full Text] [Related]
22. The Expanding Role of the BCL6 Oncoprotein as a Cancer Therapeutic Target.
Cardenas MG; Oswald E; Yu W; Xue F; MacKerell AD; Melnick AM
Clin Cancer Res; 2017 Feb; 23(4):885-893. PubMed ID: 27881582
[TBL] [Abstract][Full Text] [Related]
23. MEF2B mutations lead to deregulated expression of the oncogene BCL6 in diffuse large B cell lymphoma.
Ying CY; Dominguez-Sola D; Fabi M; Lorenz IC; Hussein S; Bansal M; Califano A; Pasqualucci L; Basso K; Dalla-Favera R
Nat Immunol; 2013 Oct; 14(10):1084-92. PubMed ID: 23974956
[TBL] [Abstract][Full Text] [Related]
24. HDAC3 Inhibition Upregulates PD-L1 Expression in B-Cell Lymphomas and Augments the Efficacy of Anti-PD-L1 Therapy.
Deng S; Hu Q; Zhang H; Yang F; Peng C; Huang C
Mol Cancer Ther; 2019 May; 18(5):900-908. PubMed ID: 30824609
[TBL] [Abstract][Full Text] [Related]
25. Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphoma.
Dupont T; Yang SN; Patel J; Hatzi K; Malik A; Tam W; Martin P; Leonard J; Melnick A; Cerchietti L
Oncotarget; 2016 Jan; 7(3):3520-32. PubMed ID: 26657288
[TBL] [Abstract][Full Text] [Related]
26. BCL6 as a therapeutic target for lymphoma.
Leeman-Neill RJ; Bhagat G
Expert Opin Ther Targets; 2018 Feb; 22(2):143-152. PubMed ID: 29262721
[TBL] [Abstract][Full Text] [Related]
27. BCL6 gene translocation in follicular lymphoma: a harbinger of eventual transformation to diffuse aggressive lymphoma.
Akasaka T; Lossos IS; Levy R
Blood; 2003 Aug; 102(4):1443-8. PubMed ID: 12738680
[TBL] [Abstract][Full Text] [Related]
28. RNAseq identification of FISH-cryptic BCL6::TP63 rearrangement in ALK-negative anaplastic large-cell lymphoma.
Ahmed N; Ketterling RP; Nowakowski GS; Dasari S; Feldman AL
Histopathology; 2022 Aug; 81(2):275-278. PubMed ID: 35586895
[No Abstract] [Full Text] [Related]
29. Evaluation of the prognostic significance of BCL6 gene expression in canine high-grade B-cell lymphoma.
Sato M; Kanemoto H; Kagawa Y; Kobayashi T; Goto-Koshino Y; Mochizuki H; Takahashi M; Fujino Y; Ohno K; Tsujimoto H
Vet J; 2012 Jan; 191(1):108-14. PubMed ID: 21277811
[TBL] [Abstract][Full Text] [Related]
30. Mutual interaction between BCL6 and miRNAs contributing to the pathogenesis of various cancers.
Wei Z; Gao W; Wu Y; Ni B; Tian Y
Clin Transl Oncol; 2015 Nov; 17(11):841-6. PubMed ID: 26108407
[TBL] [Abstract][Full Text] [Related]
31. Rearrangement of the BCL6 gene in B-cell lymphoid neoplasms: comparison with lymphomas associated with BCL2 rearrangement.
Muramatsu M; Akasaka T; Kadowaki N; Ohno H; Yamabe H; Edamura S; Dor S; Mori T; Okuma M; Fukuhara S
Br J Haematol; 1996 Jun; 93(4):911-20. PubMed ID: 8703825
[TBL] [Abstract][Full Text] [Related]
32. BCL6 represses NFkappaB activity in diffuse large B-cell lymphomas.
Perez-Rosado A; Artiga M; Vargiu P; Sanchez-Aguilera A; Alvarez-Barrientos A; Piris M
J Pathol; 2008 Mar; 214(4):498-507. PubMed ID: 18189332
[TBL] [Abstract][Full Text] [Related]
33. Overexpression of B-cell lymphoma 6 alters gene expression profile in a myeloma cell line and is associated with decreased DNA damage response.
Tahara K; Takizawa M; Yamane A; Osaki Y; Ishizaki T; Mitsui T; Yokohama A; Saitoh T; Tsukamoto N; Matsumoto M; Murakami H; Nojima Y; Handa H
Cancer Sci; 2017 Aug; 108(8):1556-1564. PubMed ID: 28544233
[TBL] [Abstract][Full Text] [Related]
34. Suppression of BCL6 function by HDAC inhibitor mediated acetylation and chromatin modification enhances BET inhibitor effects in B-cell lymphoma cells.
Cortiguera MG; García-Gaipo L; Wagner SD; León J; Batlle-López A; Delgado MD
Sci Rep; 2019 Nov; 9(1):16495. PubMed ID: 31712669
[TBL] [Abstract][Full Text] [Related]
35. BCL6 fine-tunes long-term tumor control.
Takamura S; Nomura A; Kubo M
Sci Immunol; 2023 Oct; 8(88):eadj6724. PubMed ID: 37862430
[TBL] [Abstract][Full Text] [Related]
36. LITAF, a BCL6 target gene, regulates autophagy in mature B-cell lymphomas.
Bertolo C; Roa S; Sagardoy A; Mena-Varas M; Robles EF; Martinez-Ferrandis JI; Sagaert X; Tousseyn T; Orta A; Lossos IS; Amar S; Natkunam Y; Briones J; Melnick A; Malumbres R; Martinez-Climent JA
Br J Haematol; 2013 Sep; 162(5):621-30. PubMed ID: 23795761
[TBL] [Abstract][Full Text] [Related]
37. Patients with double/triple copy number gains on C-MYC, BCL2, and/or BCL6 treated with standard chemotherapy have a similarly poor prognosis than those with high-grade B cell lymphoma with C-MYC and BCL2 and/or BCL6 rearrangements: a single-center experience on a consecutive cohort of large B cell lymphomas.
Willenbacher E; Willenbacher W; Weger R; Dominik W; Manzl C; Brunner A
Ann Hematol; 2020 Sep; 99(9):2125-2132. PubMed ID: 32613279
[TBL] [Abstract][Full Text] [Related]
38. BCL6 overexpression prevents increase in reactive oxygen species and inhibits apoptosis induced by chemotherapeutic reagents in B-cell lymphoma cells.
Kurosu T; Fukuda T; Miki T; Miura O
Oncogene; 2003 Jul; 22(29):4459-68. PubMed ID: 12881702
[TBL] [Abstract][Full Text] [Related]
39. The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells.
Phan RT; Dalla-Favera R
Nature; 2004 Dec; 432(7017):635-9. PubMed ID: 15577913
[TBL] [Abstract][Full Text] [Related]
40. Deregulation of BCL6 in non-Hodgkin lymphoma by insertion of IGH sequences in complex translocations involving band 3q27.
Chaganti SR; Rao PH; Chen W; Dyomin V; Jhanwar SC; Parsa NZ; Dalla-Favera R; Chaganti RS
Genes Chromosomes Cancer; 1998 Dec; 23(4):328-36. PubMed ID: 9824206
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
